CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 44 enrolled
Drug / intervention
Fenofibrate +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06155331
NCT06155331Phase 2Completed
CompareCT.gov

Clinical Study to Evaluate the Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients

Tanta University·interventional·Posted Dec 4, 2023·Updated Aug 19, 2025

In Brief

A Phase 2 clinical trial evaluating Fenofibrate, Placebo, and 2 other interventions for Breast Cancer Stage 2 and 3. Completed, enrolled 44 participants across 1 site.

Detailed Summary

This study aims at evaluating the possible safety and efficacy of fenofibrate in attenuating doxorubicin related cardiac toxicity in breast cancer patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer Stage 2 and 3
CountriesEgypt
Collaborators--

Timeline

Phase 2CompletedFinished
202420252026
First PostedDec 4, 2023
Enrollment StartDec 1, 2023
Primary CompletionJan 1, 2025
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 2.6 years ago

Interventions

Fenofibratedrug

It is an approved drug for hypercholesterolemia, It lowers lipid levels by activating peroxisome proliferator-activated receptor alpha (PPARα).

Placeboother

Placebo is made to look exactly like a real drug but is made of an inactive substance.

Doxorubicindrug

Anthracycline derived chemotherapy used in treatment of breast cancer

Cyclophosphamidedrug

Alkylating agent used in treatment of breast cancer